Journal of Parkinson's disease最新文献

{"title":"Practical approaches to inclusive recruitment practices in Parkinson's disease research.","authors":"Lana M Chahine, Naomi Louie, Elizabeth Disbrow, Alexis Marbach, Samantha Augenbraun, Bao-Tran Nguyen, Ashani Johnson-Turbes, Carly Parry, Sabrina Avripas, Shivika Chandra, Marissa Dean, Erin R Foster, Deborah Hall, Vanessa Hinson, Camilla Kilbane, Scott A Norris, Ashley Rawls, Cabell Jonas, Ejaz A Shamim, Lisa Shulman, Julia Staisch, Erin Furr Stimming, Tao Xie, Mackenzie Wilcox, Andrew Ameri, Sarah Breaux, Mahesh Padmanaban, Rainer von Coelln, Andrew Singleton, Cornelis Blauwendraat, Sara Bandres-Ciga, Eda Baykal-Caglar, Caitlin Kelliher, Kayleigh Greenwood, Alyssa O'Grady, J Solle, Catherine M Kopil, Maggie McGuire Kuhl","doi":"10.1177/1877718X261440708","DOIUrl":"https://doi.org/10.1177/1877718X261440708","url":null,"abstract":"<p><p>In Parkinson's disease (PD), inclusive research recruitment practices are essential to ensure that study findings are generalizable to diverse populations. The definition and implementation of inclusive recruitment practices are guided by the principles of equity, justice, engagement, and sustainability. However, practical implementation guidance is lacking. This paper shares insights from the Black and African American Connections to Parkinson's Disease (BLAAC PD) study, a PD genetics research study being conducted in the United States that enrolls individuals with and without PD. The inclusive recruitment strategy in BLAAC PD centers around four areas: training and working with study personnel toward equitable research practices, partnering with community members, creating culturally resonant study materials, and customizing practices at the local level. We provide practical examples implemented by BLAAC PD to address each of these areas. We share the materials and tools that the study utilizes for site training, recruitment, and community outreach and engagement. These approaches have potential for application in other PD research studies, to achieve greater diversity in PD research.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261440708"},"PeriodicalIF":5.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One world, one goal: Advocacy and policy for a unified Parkinson's response.","authors":"Natasha Fothergill-Misbah","doi":"10.1177/1877718X261448383","DOIUrl":"https://doi.org/10.1177/1877718X261448383","url":null,"abstract":"<p><p>Parkinson's disease is one of the fastest growing neurological disorders with regards to disability and death. Though this burden is felt globally, inequities in research, advocacy, prioritization and funding mean that the needs of people with Parkinson's disease in low- and middle-income countries, and from marginalized communities in high-income countries, remain poorly recognized. Parkinson's disease is increasingly being acknowledged as a global public health issue requiring a public health response. Global advocacy efforts, awareness-raising initiatives, research collaborations, partnerships and investment in Parkinson's disease have therefore accelerated in recent years, with the positioning of people affected by PD as authoritative voices paramount to this drive. Yet despite this progress, inequalities in access to treatments, care and support persist. Responding to the global burden posed by Parkinson's disease requires sustained, multi-sectoral, concerted action, building on an integrated and systems-oriented approach. The generation of momentum for a public health approach to Parkinson's disease must be met with implementation at the country level, alongside sufficient allocation of resources, monitoring and evaluation. The approach offered in this paper builds on the five cross-cutting strategic objectives outlined in the World Health Organization's Intersectoral global action plan on epilepsy and other neurological disorders 2022-2031 (IGAP) implementation toolkit, offering a platform to build a unified global response to Parkinson's disease. Action should therefore center on the integrated themes of (1) prioritization and governance; (2) diagnosis, treatment and care; (3) promotion and prevention; (4) research and information systems; and (5) a tailored Parkinson's disease-specific public health approach.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261448383"},"PeriodicalIF":5.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontal subcortical executive dysfunction and minor hallucinations in Parkinson's disease are linked to sensitivity to somatomotor conflicts.","authors":"Jevita Potheegadoo, Léa F Duong Phan Thanh, Fosco Bernasconi, Nathalie H Meyer, Laurent Jenni, Marie E Maradan-Gachet, Cyrille Stucker, Herberto Dhanis, Sabina Catalano Chiuvé, Julien F Bally, Mayte Castro Jimenez, Vanessa Fleury, Judit Horvath, Benoît Wicki, Javier Pagonabarraga Mora, Paul Krack, Olaf Blanke","doi":"10.1177/1877718X261440703","DOIUrl":"https://doi.org/10.1177/1877718X261440703","url":null,"abstract":"<p><p>BackgroundMinor hallucinations (MH) affect 30-60% of patients with Parkinson's disease (PD), and are considered precursors to structured visual hallucinations and cognitive decline. While the link between structured visual hallucinations and dementia is well established, the neuropsychological correlates of MH in PD remain unclear; most studies finding no significant cognitive differences between patients with MH and those without any hallucinations.ObjectivesPresence hallucinations (PH) being among the most prevalent MH in PD, we used a robotic procedure delivering somatomotor conflicts inducing PH experimentally to investigate whether sensitivity to such robot-induced PH aids in detecting cognitive differences between patients with MH and without hallucinations.Methods31 PD patients with MH (PD-MH) and 37 without hallucinations (PD-nH) underwent neuropsychological assessment and the robotic procedure inducing PH. The sensitivity to report robot-induced PH was analyzed in relation to cognitive performance in neuropsychological tests.ResultsPD-MH patients reported more robot-induced PH than PD-nH patients, supporting previous findings. While both groups showed comparable performance in neuropsychological testing, we found a significant association between increased sensitivity to the PH-induction and poorer performance in frontal subcortical cognitive functions, in PD-MH patients, but not in PD-nH patients.ConclusionsThese findings demonstrate that sensitivity to robot-induced PH reveals a previously undetected link between MH and frontal subcortical cognitive deficits in PD, pointing to shared underlying mechanisms between executive dysfunction and somatomotor processes involved in MH. This approach offers a novel and clinically valuable means of identifying early cognitive vulnerability that assessments relying only on standard testing may overlook.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261440703"},"PeriodicalIF":5.0,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical GDNF delivery methods for Parkinson's disease.","authors":"Matthias Luz, Massimo S Fiandaca, Krystof S Bankiewicz","doi":"10.1177/1877718X261444841","DOIUrl":"https://doi.org/10.1177/1877718X261444841","url":null,"abstract":"<p><p>Intracerebral delivery of glial cell line-derived neurotrophic factor (GDNF) therapeutics continues to show promise, especially in Parkinson's disease (PD). However, randomized, placebo-controlled clinical trials using GDNF protein have been inconclusive to date. A major sham-surgery controlled trial using GDNF gene therapy commenced in 2024. In this review we aim to update the reader on the evolution and current state of the art of intracerebral delivery methods for GDNF protein and gene therapy in PD clinical trials. Our intent is to increase the awareness for the importance, subtleties, and pitfalls of intracerebral delivery when reviewing current available results for these therapies and their prospects going forward. We will compare and contrast GDNF protein infusion versus gene therapy strategies and define specific anatomical and physiological details in trial participants that continue to challenge clinicians and investigators attempting to maximize therapeutic coverage of the target putamen. Despite a growing consensus that convection-enhanced delivery (CED) is the optimal intracerebral infusion strategy for localized administration of therapeutics in general and gene therapy products in particular, there is less agreement on the need for related methods, such as the co-infusion of a gadolinium contrast agent and use of intraoperative magnetic resonance imaging (iMRI) to visualize the therapeutic distribution for optimizing target coverage. Whereas certain debates will continue, most investigators and clinicians respond positively to well-designed trials providing clean, conclusive results. Information included in this review is intended to provide additional insights to interested readers, allowing better assessment of details associated with upcoming GDNF therapeutic investigations.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261444841"},"PeriodicalIF":5.0,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in sex-specific single-cell transcriptomic profiling in Parkinson's disease.","authors":"Vivien Hoof, Julia Schulze-Hentrich","doi":"10.1177/1877718X261436548","DOIUrl":"https://doi.org/10.1177/1877718X261436548","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons and the accumulation of misfolded alpha-synuclein. While traditional bulk RNA-sequencing has provided valuable insights into PD pathology, it fails to capture the complex cellular heterogeneity of the human brain. Advances in single-cell transcriptomics have revolutionized our ability to dissect this complexity, enabling the identification of rare, disease-associated cell populations, or the inference of dysregulated intercellular communication networks. In this review, we discuss methodological and analytical frameworks of single-cell RNA-sequencing and summarize key findings from recent studies using single-cell RNA-sequencing that advance our understanding of PD. We highlight how single-cell transcriptomics has refined our understanding of neuronal vulnerability and revealed critical contributions of non-neuronal cells, particularly microglia and oligodendrocytes, to disease pathology in both human postmortem tissue and experimental model systems. Finally, we discuss emerging evidence for sex-specific molecular alterations in PD and emphasize the importance of sex-aware study design and analysis in future single-cell PD research.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261436548"},"PeriodicalIF":5.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The taste of Parkinson's: How food choices reflect nutritional health.","authors":"Onanong Phokaewvarangkul, Narumol Sukmueng, Panthitra Kuwattanasuchati, Kanyawat Sanyawut, Naruemon Rattanapitak, Roongroj Bhidayasiri","doi":"10.1177/1877718X261445952","DOIUrl":"https://doi.org/10.1177/1877718X261445952","url":null,"abstract":"<p><p>IntroductionUnderweight is common in Parkinson's disease (PD), particularly in advanced stages, and is linked to malnutrition and poorer outcomes. Understanding dietary habits and nutritional status may help identify vulnerable patients.ObjectiveTo examine dietary habits and their associations with clinical characteristics in underweight versus normal-to-overweight individuals with PD.MethodsThis cross-sectional study included 70 patients with PD attending a tertiary movement disorders centre. Demographic and clinical data were obtained through interviews and medical records. Disease severity was assessed using the Hoehn & Yahr scale and the Unified Parkinson's Disease Rating Scale (UPDRS Part III and IV). Nutritional status was screened using the Mini Nutritional Assessment-Short Form (MNA-SF). Dietary habits were evaluated using a culturally adapted Thai PD dietary questionnaire, and a dietitian estimated daily caloric and fluid intake. Participants were categorized by body mass index as underweight (<18.5) or normal-to-overweight (≥18.5). Group comparisons and logistic regression analyses were performed.ResultsUnderweight patients more often consumed soft or liquid diets and had a higher prevalence of dysphagia. They reported less varied diets with lower meat and vegetable intake, although caloric and fluid intake were similar between groups. Underweight participants had lower MNA-SF scores (<i>p</i> < 0.001) and greater motor complications, including higher UPDRS Part IV scores (<i>p</i> = 0.015). Female gender (OR 18.51), dysphagia (OR 5.97), and dyskinesia (OR 2.03) were independently associated with underweight status.ConclusionUnderweight in PD is associated with female gender, dysphagia, and dyskinesia. Early nutritional screening and management of dysphagia and motor complications may improve outcomes.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261445952"},"PeriodicalIF":5.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"<i>To Bean or Not to Bean</i>\": Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about <i>Mucuna pruriens</i>.","authors":"Roberto Cilia, Regina Katzenschlager","doi":"10.1177/1877718X261442075","DOIUrl":"https://doi.org/10.1177/1877718X261442075","url":null,"abstract":"<p><p><i>Mucuna pruriens</i> (MP), a leguminous plant naturally rich in levodopa, has regained attention as both a traditional remedy and a potential therapeutic option for Parkinson's disease (PD). Its appeal is shaped by contrasting contexts: in low- and middle-income countries (LMICs), MP may represent a cost-effective, locally cultivable alternative where access to levodopa-based medications is severely limited; in high-income countries, patients are often drawn to its \"natural\" label, perceiving it as safer or more holistic than synthetic drugs. Evidence from randomised and open-label clinical trials demonstrates that properly processed MP preparations provide symptomatic benefits comparable to commercial levodopa, though long-term safety data are still scarce. However, despite its natural origin, MP is a potent dopaminergic therapy requiring the same caution as commercially available levodopa-based medications. Overuse and unsupervised self-medication have been associated with dyskinesia, dopamine dysregulation syndrome, and psychiatric complications, while cases of toxicity from improper seed preparation underscore its risks. In our view, a balanced perspective is essential: while MP holds promise as a sustainable therapeutic option in LMICs, its use should remain restricted to clinical trials or neurologist-led protocols until more robust evidence of long-term safety and efficacy emerges.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261442075"},"PeriodicalIF":5.0,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential effects of levodopa on social cognition in people with Parkinson's disease.","authors":"Teodor Danaila, Élise Métereau, Hélène Klinger, Adélaide Jaulent, Océane Porte, Léon Tremblay, Paul Jaulent, Chloé Laurencin, Stéphane Prange, Stéphane Thobois","doi":"10.1177/1877718X261435304","DOIUrl":"https://doi.org/10.1177/1877718X261435304","url":null,"abstract":"<p><p>Social cognition impairment is a frequent non-motor feature of Parkinson's disease. While dopaminergic therapy modulates motor symptoms, its effects on social cognition remain incompletely understood. We investigated the effects of acute levodopa administration on cognitive and affective Theory of Mind, as well as on emotional resonance to dynamic whole-body social interactions, in 36 people with Parkinson's disease with motor fluctuations and 14 matched healthy controls. Social cognition was assessed using the Mini-Social Cognition and Emotional Assessment (Mini-SEA) and a point-light display task indexing emotional resonance through emotional valence ratings. Patients were evaluated in OFF and ON states during an acute dopaminergic challenge performed according to the CAPSIT-PD protocol, with responsiveness defined as an improvement greater than 50% on the MDS-UPDRS part III. Compared with healthy controls, patients showed impaired cognitive Theory of Mind performance, particularly on the faux pas subtest (p = 0.0001), while affective Theory of Mind based on facial emotion recognition was preserved. Acute levodopa did not improve cognitive or affective Theory of Mind (faux pas OFF vs ON, p = 0.7049). In contrast, emotional resonance was impaired in the OFF state and selectively improved in the ON state, with increased ratings of positive (p = 0.0035) and negative (p = 0.0387) emotional valence. These findings demonstrate a dissociation between Theory of Mind and emotional resonance in Parkinson's disease and show that acute levodopa selectively modulates emotional resonance without restoring Theory of Mind abilities.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261435304"},"PeriodicalIF":5.0,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parkinson's disease and the concept of resilience, cognitive, and motor reserve.","authors":"Merle C Hoenig","doi":"10.1177/1877718X261444486","DOIUrl":"https://doi.org/10.1177/1877718X261444486","url":null,"abstract":"<p><p>Parkinson's disease (PD) shows pronounced clinical heterogeneity, with individuals presenting differing cognitive and motor trajectories despite similar levels of neurodegeneration, in particular striatal dopamine terminal loss. This variability underscores the relevance of considering resilience mechanisms, particularly cognitive and motor reserve, that may support preserved function in the face of progressive pathology and neurodegeneration. Building on a previously proposed conceptual framework of resilience in PD, this review provides an updated and integrative synthesis of recent evidence, including longitudinal studies, neuroimaging findings, and emerging insights into lifestyle-related factors. The review further extends the existing framework by addressing current methodological challenges and outlining future directions for incorporating resilience into neuroimaging research, biological staging models, and personalized intervention strategies in PD. Together, this work emphasizes the growing importance of resilience research in PD and its potential to improve prognostic accuracy and inform more precise and individualized therapeutic approaches.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261444486"},"PeriodicalIF":5.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers and enablers to cognitive assessment in Parkinson's disease: A qualitative contextual inquiry.","authors":"Deborah Brooks, Kirstine Shrubsole, Deepa Sriram, Jihyun Yang, Leander K Mitchell, Peter Worthy, Elton Lobo, Dana Pourzinal, Nadeeka N Dissanayaka","doi":"10.1177/1877718X261440707","DOIUrl":"https://doi.org/10.1177/1877718X261440707","url":null,"abstract":"<p><p>BackgroundCognitive impairment in Parkinson's disease (PD) is often overlooked, despite increased risk of dementia in PD. 'PDCogniCare' is an innovation aiming to improve access to cognitive assessments, for earlier diagnosis and care. This study explored barriers and enablers to cognitive assessment in PD, to inform implementation of 'PDCogniCare'.MethodsParticipants included ten people with PD, one caregiver, and nineteen health professionals within two Australian public health services. Semi-structured interviews were informed by the Theoretical Domains Framework (TDF) and the Consolidated Framework for Implementation Research (CFIR). Deductive and inductive analysis was utilised. Barriers were mapped to the CFIR-ERIC (Expert Recommendations for Implementing Change) matching tool to develop implementation strategies.ResultsSeven themes were identified: 1) lack of discussion about cognitive impairment limits access to cognitive assessments and interventions; 2) clinicians need to 'be on board with cognition'; 3) availability of clinic resources impacts delivery of cognitive screens and assessments; 4) variability of clinician decision-making processes to screen or refer patients for neuropsychological assessment; 5) impact of undergoing neuropsychological assessments on people living with PD; 6) uncertainty over benefits of cognitive assessment in changing clinical management; and 7) perceived advantages of 'PDCogniCare' over current practice. Strategies to address identified barriers included: clinician education and training, additional resource allocation, support and feedback, and involving patient/consumer advocates.ConclusionsSeveral barriers and enablers to cognitive assessment in PD were identified, relating to health professional knowledge, beliefs, context and resources. Strategies that address these may improve clinical practice for more proactive treatment and care.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X261440707"},"PeriodicalIF":5.0,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147774544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}